RBBP9 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL213731	0.67	5/20
SCHEMBL213802	0.59	5/20
SCHEMBL213126	0.59	5/20
SCHEMBL215432	0.59	5/20
SCHEMBL4918762	0.57	5/20
SCHEMBL4920061	0.57	5/20
SCHEMBL212884	0.55	5/20
SCHEMBL213922	0.52	5/20
SCHEMBL212121	0.51	5/20
SCHEMBL21836242	0.51	5/20
SCHEMBL21836245	0.51	5/20
SCHEMBL1254922	0.49	5/20
Acetic Acid (SCHEMBL3134326)	0.47	5/20
SCHEMBL5560181	0.47	5/20
SCHEMBL14152809	0.45	5/20
SCHEMBL10716861	0.44	5/20
SCHEMBL5609136	0.44	5/20
SCHEMBL4391375	0.43	5/20
Bicarbonate (SCHEMBL10505047)	0.43	5/20
SCHEMBL17201513	0.43	5/20

Clinical trials — most relevant to RBBP9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor	PHASE1/PHASE2	NOT_YET_RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Studying Health Outcomes After Treatment in Patients With Retinoblastoma	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
PCM1-JAK2 in Therapy Related Neoplasms	nan	UNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy	nan	COMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RBBP9 binder may also engage these)

Protein	Name	Similarity
O88851	—	1.000	O88851 →
O88350	—	1.000	O88350 →
P03958	—	0.972	P03958 →
P24518	—	0.972	P24518 →
A8E657	—	0.971	A8E657 →
Q9UDR5	—	0.971	Q9UDR5 →
P0AC90	—	0.970	P0AC90 →
O88428	—	0.970	O88428 →
O35826	—	0.970	O35826 →
Q8K3X3	—	0.969	Q8K3X3 →
P58674	—	0.969	P58674 →
P13228	—	0.969	P13228 →
Q7TQ49	—	0.969	Q7TQ49 →
P26425	—	0.969	P26425 →
Q8VYX1	—	0.969	Q8VYX1 →
P27278	—	0.969	P27278 →
Q56872	—	0.969	Q56872 →
Q3M8X6	—	0.969	Q3M8X6 →
B7MMH6	—	0.969	B7MMH6 →
Q867C9	—	0.969	Q867C9 →
NQO1	NAD(P)H dehydrogenase [quinone] 1	0.969	landscape →
Q6G7C2	—	0.968	Q6G7C2 →
O02373	—	0.968	O02373 →
P47859	—	0.968	P47859 →
P17571	—	0.968	P17571 →
Q9C8J4	—	0.968	Q9C8J4 →
A8Y0L5	—	0.968	A8Y0L5 →
Q5RA68	—	0.968	Q5RA68 →
Q8A0V3	—	0.968	Q8A0V3 →
P0A8Z8	—	0.968	P0A8Z8 →